Eisai

Historical price data

Eisai is a fully integrated, patient-centric biopharmaceutical company with a mission to give first thought to patients and their families. Its strategic focus on neurology and oncology has yielded landmark achievements, most notably the commercialization of the first disease-modifying Alzheimer's therapy, LEQEMBI, in partnership with Biogen. The company complements its commercial success with a deep, long-standing commitment to sustainability and global health, distributing billions of treatments for neglected tropical diseases. Financially robust and strategically disciplined, Eisai is leveraging its neuroscience leadership to expand its oncology portfolio and solidify its long-term growth trajectory.

Integrated small molecule discovery and development with deep expertise in neurology (neurodegenerative diseases) and oncology (tyrosine kinase inhibitors), driven by a patient-centric research philosophy.

In Alzheimer's, faces direct competition from Eli Lilly's donanemab and other amyloid-targeting therapies. In oncology, LENVIMA competes with other VEGF inhibitors and combo regimens, while taletrectinib will compete in the niche ROS1+ NSCLC market. Eisai differentiates via its integrated 'hhc' approach and deep global health commitment.